GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (tezepelumab) as a potential treatment for ...

With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...